Inhibition of MMP-9 attenuates hypertensive cerebrovascular dysfunction in Dahl salt-sensitive rats

Molecular and Cellular Biochemistry

Volumn 413, Issue 1-2, 2016, Pages 25-35

  Kalani, Anuradha ^a   Pushpakumar, Sathnur B ^a   Vacek, Jonathan C ^a   Tyagi, Suresh C ^a   Tyagi, Neetu ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cerebrovascular; Hypertension; MMP 9; ROS

Indexed keywords

CLAUDIN 5; GELATIN; GELATINASE B; GLUTATHIONE; ILOMASTAT; MALONALDEHYDE; MESSENGER RNA; NITRILE; NITRITE; OCCLUDIN; REACTIVE OXYGEN METABOLITE; TIGHT JUNCTION PROTEIN; DIPEPTIDE; MATRIX METALLOPROTEINASE INHIBITOR; MMP9 PROTEIN, RAT; N-(2(R)-2-(HYDROXAMIDOCARBONYLMETHYL)-4-METHYLPENTANOYL)-L-TRYPTOPHAN METHYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH SODIUM INTAKE; HYPERTENSION; HYPERTENSIVE CEREBROPATHY; IMMUNOHISTOCHEMISTRY; MALE; MEAN ARTERIAL PRESSURE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; DAHL RAT; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS RAT; METABOLISM;

ANIMALS; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; DIPEPTIDES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; HYPERTENSION; INJECTIONS, INTRAPERITONEAL; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; RATS; RATS, INBRED DAHL; RATS, INBRED LEW; TIGHT JUNCTION PROTEINS;

EID: 84957427466     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2623-8     Document Type: Article

References (48)

1. Gorelick PB (2002) New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 1:149–156
2. Freis ED (1992) The role of salt in hypertension. Blood Press 1:196–200
3. Swales JD (1992) Salt and blood pressure. Blood Press 1:201–204
4. Meneely GR, Ball CO (1958) Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med 25:713–725
5. Kawasaki T, Delea CS, Bartter FC, Smith H (1978) The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med 64:193–198
6. Weinberger MH (1996) Salt sensitivity of blood pressure in humans. Hypertension 27:481–490
7. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6:650–661. doi:10.1038/nrd2368
8. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173–185. doi:10.1124/pr.57.2.4
9. Mark KS, Davis TP (2002) Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 282:H1485–H1494. doi:10.1152/ajpheart.00645.2001
10. Baumbach GL, Heistad DD (1988) Cerebral circulation in chronic arterial hypertension. Hypertension 12:89–95
11. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516. doi:10.1146/annurev.cellbio.17.1.463
12. Cauwe B, Van den Steen PE, Opdenakker G (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42:113–185. doi:10.1080/10409230701340019
13. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, Tedgui A, Dussaule JC, Lehoux S (2007) Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50:212–218. doi:10.1161/HYPERTENSIONAHA.107.089631
14. Kalani A, Kamat PK, Chaturvedi P, Tyagi SC, Tyagi N (2014) Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci 107:1–7. doi:10.1016/j.lfs.2014.04.018
15. Kalani A, Kamat PK, Familtseva A, Chaturvedi P, Muradashvili N, Narayanan N, Tyagi SC, Tyagi N (2014) Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism. J Cereb Blood Flow Metab 34:1212–1222. doi:10.1038/jcbfm.2014.74
16. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399–1406. doi:10.1161/01.STR.0000223001.06264.af
17. Kalani A, Kamat PK, Givvimani S, Brown K, Metreveli N, Tyagi SC, Tyagi N (2014) Nutri-epigenetics ameliorates blood-brain barrier damage and neurodegeneration in hyperhomocysteinemia: role of folic acid. J Mol Neurosci 52:202–215. doi:10.1007/s12031-013-0122-5
18. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC (2006) Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol 290:H1206–H1213. doi:10.1152/ajpheart.00376.2005
19. Chen F, Ohashi N, Li W, Eckman C, Nguyen JH (2009) Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure. Hepatology 50:1914–1923. doi:10.1002/hep.23203
20. Muradashvili N, Tyagi R, Metreveli N, Tyagi SC, Lominadze D (2014) Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia. J Cereb Blood Flow Metab 34:1472–1482. doi:10.1038/jcbfm.2014.102
21. Pushpakumar SB, Kundu S, Metreveli N, Tyagi SC, Sen U (2013) Matrix metalloproteinase inhibition mitigates renovascular remodeling in salt-sensitive hypertension. Physiol Rep 1:e00063. doi:10.1002/phy2.63
22. Kamat PK, Tota S, Saxena G, Shukla R, Nath C (2010) Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 1309:66–74. doi:10.1016/j.brainres.2009.10.064
23. Iwai J, Heine M (1986) Dahl salt-sensitive rats and human essential hypertension. J Hypertens Suppl 4:S29–S31
24. Rapp JP (1982) Dahl salt-susceptible and salt-resistant rats. A review. Hypertension 4:753–763
25. Bright R, Steinberg GK, Mochly-Rosen D (2007) DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Brain Res 1144:146–155. doi:10.1016/j.brainres.2007.01.113
26. Zozulya AL, Reinke E, Baiu DC, Karman J, Sandor M, Fabry Z (2007) Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. J Immunol 178:520–529
27. Wang J, Tsirka SE (2005) Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128:1622–1633. doi:10.1093/brain/awh489
28. Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H, Abe M, Koga M, Kanda T (2014) Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 85:419–430. doi:10.1136/jnnp-2013-305907
29. Fingleton B (2007) Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13:333–346
30. Cui J, Chen S, Zhang C, Meng F, Wu W, Hu R, Hadass O, Lehmidi T, Blair GJ, Lee M, Chang M, Mobashery S, Sun GY, Gu Z (2012) Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener 7:21. doi:10.1186/1750-1326-7-21
31. Iadecola C, Davisson RL (2008) Hypertension and cerebrovascular dysfunction. Cell Metab 7:476–484. doi:10.1016/j.cmet.2008.03.010
32. Tyagi N, Gillespie W, Vacek JC, Sen U, Tyagi SC, Lominadze D (2009) Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol 220:257–266. doi:10.1002/jcp.21757
33. Tyagi N, Qipshidze N, Munjal C, Vacek JC, Metreveli N, Givvimani S, Tyagi SC (2012) Tetrahydrocurcumin ameliorates homocysteinylated cytochrome-c mediated autophagy in hyperhomocysteinemia mice after cerebral ischemia. J Mol Neurosci 47:128–138. doi:10.1007/s12031-011-9695-z
34. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH (2001) Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393–1400. doi:10.1097/00004647-200112000-00003
35. Reinhard SM, Razak K, Ethell IM (2015) A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci 9:280. doi:10.3389/fncel.2015.00280
36. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES Jr (1997) Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 41:642–666 (discussion 646-7)
37. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, Sharp FR (2014) Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab 34:185–199. doi:10.1038/jcbfm.2013.203
38. Kalani A, Kamat PK, Tyagi N (2015) Diabetic stroke severity: epigenetic remodeling and Neuro-glio-vascular dysfunction. Diabetes. doi:10.2337/db15-0422
39. Touyz RM (2006) Mitochondrial redox control of matrix metalloproteinase signaling in resistance arteries. Arterioscler Thromb Vasc Biol 26:685–688. doi:10.1161/01.ATV.0000216428.90962.60
40. Garcia-Alloza M, Prada C, Lattarulo C, Fine S, Borrelli LA, Betensky R, Greenberg SM, Frosch MP, Bacskai BJ (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J Neurochem 109:1636–1647. doi:10.1111/j.1471-4159.2009.06096.x
41. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127. doi:10.1038/nature03688
42. Girouard H, Park L, Anrather J, Zhou P, Iadecola C (2006) Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol 26:826–832. doi:10.1161/01.ATV.0000205849.22807.6e
43. Didion SP, Kinzenbaw DA, Faraci FM (2005) Critical role for CuZn-superoxide dismutase in preventing angiotensin II-induced endothelial dysfunction. Hypertension 46:1147–1153. doi:10.1161/01.HYP.0000187532.80697.15
44. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53. doi:10.1038/nrn1824
45. Wong V, Gumbiner BM (1997) A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol 136:399–409
46. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161:653–660. doi:10.1083/jcb.200302070
47. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697–709. doi:10.1038/sj.jcbfm.9600375
48. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50:202–211. doi:10.1007/s00125-006-0485-z